Latest Breaking News On - Richard steinhart - Page 1 : comparemela.com

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q1 2024 Earnings Call Transcript

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q1 2024 Earnings Call Transcript
insidermonkey.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from insidermonkey.com Daily Mail and Mail on Sunday newspapers.

JapanMizuhoHokkaidoUnited statesAmericaRob risingerRam selvarajuCanaccord genuityVimal mehtaSumant kulkarniRichard steinhartAvantika joshiFrank yoccaAlec stranahanMatt wileyColin bristow

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q4 2023 Earnings Call Transcript

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q4 2023 Earnings Call Transcript March 12, 2024 BioXcel Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.76, expectations were $-0.98. BioXcel Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, and welcome […]

Richard steinhartVimal mehtaMost advanced countries in internationalXcel therapeuticsWith the highest numberInternet usersAdvanced countries

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q3 2023 Earnings Call Transcript

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q3 2023 Earnings Call Transcript November 14, 2023 BioXcel Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-1.72 EPS, expectations were $-1.29. Operator: Good morning, and welcome to the BioXcel Therapeutics Conference Call, which will cover its alignment with the FDA on its TRANQUILITY program, provide an update on strategic […]

QatarUnited statesAmericaVimal mehtaGreg harrisonRichard steinhartColumbia universityQatar investment authorityWhite house office of national drug controlOaktree capital managementQatar investmentOaktree capitalWhite house officeNational drug controlXcel therapeuticsHedge funds

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q3 2023 Earnings Call Transcript

Operator: Good morning, and welcome to the BioXcel Therapeutics Conference Call, which will cover its alignment with the FDA on its TRANQUILITY program, provide an update on strategic financing, and review.

QatarUnited statesPhiladelphiaPennsylvaniaWhite houseDistrict of columbiaAmericaMatt wileyVince oneillCanaccord genuityVimal mehtaFrank yoccaSumant kulkarniGreg harrisonRob risingerRam selvaraju

BioXcel Therapeutics : Other Information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securit.

DelawareUnited statesWashingtonRichard steinhartSecurities exchangeCommission file numberCompany tranquility ii phaseK while the companyBioxcel therapeutics incDrug administrationExchange actXcel therapeuticsZip codeSecurities actSecurities exchange actBioxcel therapeutics